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Objective: Primary Budd-Chiari syndrome (BCS) is a rare form of hepatic venous outflow obstruction at the suprahepatic
inferior vena cava (IVC), the hepatic veins, or both. We assessed our 4-year experience in the management of BCS to
evaluate the results of our methods of care.
Methods: We conducted a retrospective review of a nonrandomized clinical trial conducted in three teaching hospitals.
Among 28 primary BCS patients, 9 remained in medical treatment only, and 19 who failed to respond to medical
treatment received additional endovascular (n  17) or surgical therapy (n  2). Nine underwent IVC balloon
angioplasty alone, 6 had angioplasty plus stents, and 2 had transjugular intrahepatic portosystemic shunts (TIPS) for
hepatic vein lesions. One patient had a mesoatrial bypass; another had liver transplantation. Immediate response to the
therapy was assessed with angiography and ultrasonography based on anatomic and/or hemodynamic correction or
reduction of the lesion. Subsequent assessment of portal hypertension status was made with periodic clinical and
laboratory evaluation (eg, ultrasonography, liver biopsy).
Results:Twenty-six patients had had IVC stenosis or occlusion by focal or segmental lesion. Two patients had hepatic vein
outlet obstruction. There was no evidence of coagulopathy as the pathogenesis; all were related to membranous
obstruction of the vena cava. Excellent immediate response to the endovascular therapy and subsequent relief of portal
hypertension were achieved in 14 patients. Four patients had restenosis or progression of the residual lesion within 2
years; three responded to repeated stenting. Primary patency was 76.5%, and primary assisted patency was 94.1%. Two
patients with TIPS and two with surgical therapy maintained excellent results. The medical treatment remained effective
only in a limited group of 6 (21.4%) of the 28 patients.
Conclusions: In BCS, both endovascular and surgical interventions provide excellent results and potentially halt liver
parenchymal deterioration caused by portal hypertension. Liver transplantation remains the ultimate solution for
advanced liver failure. ( J Vasc Surg 2006;43:101-8.)Hepatic venous outflow obstruction at the suprahe-
patic inferior vena cava (IVC), the hepatic veins, or both,
has been known as Budd-Chiari syndrome (BCS) regard-
less of its etiologies (eg, primary and secondary) and patho-
genesis (eg, congenital, inflammatory, infectious origin, or
a combination).1-6 Primary BCS is a relatively rare condi-
tion, with geographic variances in etiologic and predispos-
ing factors, with striking difference between African and
Asian patients and Caucasian (Western) patients.4-9 The
developmental anomaly theory is mostly compatible with
African and Asian patients as its etiopathogenesis, while the
thrombosis theory is more compatible to Caucasian pa-
tients.4-7
Management strategy also remains critical and includes
decompression procedures vs curative radical proce-
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doi:10.1016/j.jvs.2005.09.003dures.10-13 The optimum combination of various surgical
and endovascular procedures14-17 is also not quite clear,
especially when BCS is considered as a precancerous le-
sion.18-20
We assessed our experiences in the management of
suprahepatic IVC, hepatic vein obstruction, or both, by
primary BCS to evaluate the results of our methods of care.
METHODS AND PATIENTS
A retrospective analysis of 28 patients (13 men, 15
women; mean age, 43.2 years) was conducted for a 4-year
period between September 1994 and August 2001 at Sam-
sung Medical Center and its affiliated hospitals of
Sungkyunkwan University, Seoul, Korea. Nineteen pa-
tients (11 men, 8 women; aged 28 to 68 years; mean, 45
years) who failed to respond to medical therapy with evi-
dence of progress for a minimum 1-year period were se-
lected for endovascular, or surgical treatment, or both. The
other nine patients (2 men, 7 women; aged 24 to 59 years;
mean, 41.4 years) with a satisfactory response to the med-
ical therapy remained in the medical therapy group.
Diagnostic evaluation of BCS included functional and
anatomic assessment of the IVC and hepatic veins with
laboratory and chemical tests as well as other noninvasive
tests. In addition to liver chemistry and hepatitis profile, a
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the coagulopathy as predisposing factor.
Duplex ultrasonographic studies21-23 and contrast-en-
hanced computed tomography (CT) scans 24 of IVC and
hepatic veins were performed in all 28 patients to assess the
status of the intrahepatic venous collateral and portal vein
system and hepatic venous outflow along the IVC. Signs of
obstruction of hepatic venous outflow, abnormalities in the
direction of flow in the hepatic veins, and communicating
vessels between the hepatic veins were assessed with real-
time imaging by the pulsed Doppler analysis (Fig 1). Mag-
netic resonance (MR) imaging or MR angiography,25 or
both, a were added selectively when indicated.
A baseline liver biopsy specimen was obtained in most
patients, but a follow-up biopsy was performed only when
evidence showed that the disease was progressing. Trans-
femoral IVC angiography was performed in all patients as a
road map for the further treatment procedure.
Selective portal vein studies with direct splenoportog-
raphy, celiac-hepatic angiography, percutaneous transhe-
patic hepatic venography, or a combination, were limited to
A
C
Fig 1. Duplex ultrasonographic findings of various int
(BCS). A, Collateral vein is displayed as typical “ring”
middle hepatic veins (MHV), reflecting hepatic venous o
blood flow following the thrombosis. C, Focal stenosis o
of hepatic venous outflow obstruction. It is most probab
common cause of primary BCS. D, Segmental stenosis ofthose candidates for a transjugular intrahepatic portosys-temic shunt (TIPS) or other surgical decompression proce-
dures for portal hypertension.10,11
The medical therapy included general care for portal
hypertension, liver cirrhosis, and ascites with diuretics,
hepatotonic measurement with nutritional support, and
empirical treatment of various symptoms and signs of portal
hypertension. Anticoagulation therapy was not included.
The response to medical treatment was assessed every 6
months with biochemical liver function tests and ultrasono-
graphic evaluation of liver parenchymal status.
Among 19 patients, 17 received endovascular treat-
ment and dilatation to the suprahepatic IVC or hepatic vein
lesions, or both. Two underwent surgery—bypass for the
complete obstruction of long segment of suprahepatic IVC
with massive thrombosis, and transplantation for advanced
cirrhosis—because endovascular treatment was neither in-
dicated nor technically feasible.
Nine patients had IVC balloon angioplasty alone to the
focal (n  8) or short (2.5 cm long) segmental (n  1)
stenosis caused by membranous obstruction lesions of the
IVC (MOVC). Six who did not adequately respond to the
atic conditions due to primary Budd-Chiari syndrome
connection (white arrows) between right (RMV) and
obstruction. B, Left hepatic vein demonstrates a lack of
rahepatic inferior vena cava (IVC) is shown as the cause
e to the membranous obstruction of the IVC, the most
(2.87 cm) is shown with evidence of portal hypertension.B
D
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Two had TIPS to relieve hepatic venous outlet obstruction
caused by lesions between IVC and hepatic veins.11
Inferior vena cava balloon angioplasty was done mostly
by the transfemoral approach, except in the patients who
required the “kissing balloon technique” via a simultaneous
transjugular approach. Various angioplasty catheters (5- to
18-mm balloon) (Cook, Bloomington, Ind) were used for
the preliminary and final dilatation together with conven-
tional spring-coil and laminated hydrophilic guide wires
with floppy tips or stiff end. Wallstents (Boston Scientific,
Natick, Mass) were used for the stenting procedures.
One patient, who had a history of failed angioplasty and
occlusion of IVC with extensive thrombosis, had a me-
soatrial bypass26,27 from the superior mesenteric vein to the
right atrium. An 18-mm ringed polytetrafluoroethylene
graft was used to relieve progressive liver cirrhosis and
portal hypertension. Another patient, who had a failed/
thrombosed cavoatrial bypass done 2 years before the re-
ferral, had cadaver donor liver transplantation10,12for a
rapidly deteriorating liver condition.
The immediate results of the treatment were assessed
for anatomic and hemodynamic responses to the proce-
dures:
● Excellent—anatomically complete to near-complete
dilatation of the stenosis and/or hemodynamically
comparable reduction of the pressure gradient;
● Good—substantial correction of stenosis with minimal
to 25% to 30% residual lesion anatomically and/or
comparable residual pressure gradient;
● Fair—significant (50%) residual lesion with im-
proved pressure gradient;
● Poor—substantial (50%) residual lesion with mini-
mum to no pressure gradient improvement.
For the endovascular procedures, heparin was used
only during the procedure unless simultaneous thrombol-
ysis was required; heparin use was then extended for 1
week, followed by sodium warfarin for 1 month (interna-
tional normalized ratio, 2.0). All other routine endovascu-
lar patients were on the antiplatelet agent for only 1 month
after the procedures. The patient who had bypass surgery
was also prescribed an antiplatelet agent for 1 month.
Follow-up assessment for the treatment results was
made of all 19 patients, with a clinical evaluation as well as
an ultrasonography study and liver function tests, starting
at 2 weeks and continuing at 1 month, 2 months, and 3
months, and then at 6-month intervals thereafter for a
minimum of 4 years. Additional tests (eg, CT/MR angiog-
raphy, liver biopsy) were performed when indicated.
Clinical criteria for the relief of portal hypertension
following the treatment include:
● Excellent—complete to near-complete relieve of as-
cites and/or hepatomegaly with compatible laboratory
findings (eg, disappearance of hepatic parenchymal
congestion on ultrasound evaluation);● Good—substantial relief of clinical evidence of portal
hypertension with compatible laboratory improve-
ment; and
● Fair—noticeable responses with minimal clinical
improvement.
Liver parenchymal status was separately assessed by
duplex ultrasound study in all 19 patients. Parenchymal
congestion was graded as remained, improved, relieved, or
progressive by two independent radiologists. A liver biopsy,
mostly done percutaneously, was also included in 10 pa-
tients with known cirrhosis to evaluate the treatment re-
sponse. Cirrhosis was graded as improved, stable, or progres-
sive by the histopathologists.
RESULTS
All 28 patients were confirmed as having the primary
type of BCS due to suprahepatic IVC stenosis or occlu-
sion in 26 patients or hepatic vein outlet obstructive
lesions in two patients on ultrasonographic study. All the
IVC lesions were either focal stenoses or occlusions with
or without membranous lesions in 14, or segmental
stenoses or occlusions in 12. All IVC lesions had at least
one patent hepatic vein opening, mostly with the right
hepatic vein in 22 into the IVC below the site of occlu-
sion; the right hepatic vein had generally extensive col-
lateral channels of intrahepatic veins to communicate
with left or middle hepatic vein (Fig 1).
Other etiologic and predisposing factors, especially hy-
percoagulopathy, were completely ruled out in the 28
patients. They had an average of 3.6 years (2.8 to 4.1 years)
of clinical history reflecting chronic portal hypertension
before the diagnosis of primary BCS, but their liver profiles
showed remarkably well-preserved liver function, except
for moderate to severe hepatic congestion.
They have shown various clinical symptoms and signs;
ascites was the most common finding together with hepa-
tomegaly (n  24, 86%), back or flank collateral veins was
the second most common findings (n  20, 71%), pain or
ache in the abdomen (n 18, 64%), splenomegaly (n 14,
50%), jaundice (n  9, 32%), and gastrointestinal bleeding
(n  2, 7%). Most were remarkably free from chronic
venous hypertension of the lower extremity, only a small
group of six patients had minimal leg swelling, and there
were no cases of venous claudication.
Procedures in the 17 endovascular patients were tech-
nically successful, with excellent to good responses as im-
mediate outcomes and subsequent relief of portal hyper-
tension in 14 (82%) (Fig 1): angioplasty alone (78%) to the
focal stenosis in 7, angioplasty plus stent (83%) to the focal
and segmental stenosis in 5, and TIPS (100%) to the
hepatic vein outlet obstruction in 2.
Nine patients were treated with angioplasty alone, and
all eight focal lesions showed immediate or technical suc-
cess with excellent results in seven and good results in one.
One segmental lesion had fair response, but the patient
refused to have additional stenting simultaneously to im-
prove the result.
ient.
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immediate or technical success was achieved in the two
focal lesions, and three of four segmental lesions also had
excellent responses. The response in on segmental lesion
remained poor tominimum, but the patient refused to have
a retrial of the stent procedure (Fig 2). The average pressure
gradient of 28.2 mm Hg was reduced to 10.6 mm Hg by
the successful procedures.
Two patients were treated with TIPS using 10-mm
diameter Wallstents; both had excellent responses, with
immediate relief of hepatic vein outlet obstruction. The
pressure gradient has shown a substantial reduction, from
29.1mm Hg to 10.2 mm Hg (patient 1) and 23.8 mm Hg
to 9.2 mm Hg (patient 2) (Fig 3).
All 14 patients (angioplasty alone in 7, angioplasty plus
stent in 5, and TIPS in 2) who had excellent technical
response to the endovascular procedures subsequently
achieved excellent relief of portal hypertension within 6
months, with compatible improvement of clinical (eg, as-
cites and hepatomegaly) and laboratory findings (eg, liver
profiles, hepatic congestion finding on ultrasound study).
Among three other patients, two showed fair to minimum
improvement by clinical and laboratory evaluations at the
subsequent 6-month follow-up, and one, with advanced
cirrhosis, showed poor to no response, which were compat-
ible with ultrasound findings.
In four patients in the endovascular group (n  7),
restenoses or progression of residual stenosis developed
within 2 years along the region previously treated with
BA
Fig 2. Endovascular management of focal stenotic lesion
membranes (arrows) as the cause of obstruction; it depic
Budd-Chiari syndrome. B, Angiographic finding display
hemodynamic response to angioplasty alone to relieve
remains despite complete reduction of the pressure gradendovascular dilatation, for a failure rate of 23.5%.Among the patients treated with angioplasty alone, one
with a segmental lesion who had a fair response to the inial
treatment showed deterioration within 6 months and later
underwent an additional stenting procedure; another with
a focal lesion that responded well to the initial angioplasty
was also found to be in near-occlusive status after she
missed her regular follow-up assessments for 1 year. Two
patients treated with angioplasty plus stent for the segmen-
tal lesions, including one who failed to respond initially,
were found to have further progress of the lesion after they
missed follow-up for 2 years. However, all four patients
immediately underwent reintervention for the occlusion or
restenosis of IVC with a stent, two of which required
combined thrombolytic therapy. Three patients had an
excellent outcome, but one did not improve after this
second endovascular procedure and refused bypass surgery
despite steady deterioration. Therefore, during a minimum
4-year follow-up (average, 4.5 years), 17 endovascular pro-
cedures had a primary patency rate of 76.5%, and the
primary assisted patency rate was 94.1%. No deaths oc-
curred among this endovascular group during the fol-
low-up period.
Mesoatrial bypass achieved immediate reduction of
portal pressure from 50 to 8 cm H2O intraoperatively and
maintained excellent patency, with complete relief of portal
hypertension (Fig 4). Steady clinical improvement, such as
disappearance of ascites, abdominal wall collaterals, and
hepatomegaly, was accompanied by compatible improve-
ment of the liver status as confirmed by periodic ultrasound
C
balloon angioplasty alone. A, Duplex scan demonstrates
al stenosis of the inferior vena cava (IVC) as the cause of
ht stenosis of suprahepatic IVC. C, Shows the excellent
l hypertension subsequently; a residual stenosis of 31%with
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function throughout the follow-up period (4.2 years), and
the transplanted liver had no evidence of BCS or cancer
development. The recipient’s explanted liver was found to
have early stage hepatocellular carcinoma (HCC).18-20
Among the endovascular/surgical group, ultrasound
evaluation of liver parenchymal congestion showed 15 re-
lieved, 3 improved, and 1 progressed, which were directly
proportional to the anatomic and hemodynamic response
to the therapy.
The liver biopsy specimens from 10 cirrhotic patients
showed a variable degree of outflow obstruction and hep-
atocellular damage from sinusoidal dilation with centri-
lobular congestion to hepatocyte necrosis. But the findings
of mild to moderate fibrosis were common in the majority.
Among these 10 patients, 5 remained histologically stable,
including 1 who had an unsatisfactory response to the
angioplasty alone, and 2 who improved28 after endovascu-
lar/bypass therapy. Three patients deteriorated, including
one with good immediate response and subsequent suc-
cessful decompression of portal hypertension. None of
these three showed evidence of coinfection with hepatitis B
and C viruses. Two developed de novo HCC during the
follow-up period of 4.7 years and are currently on chemo-
embolization therapy.
Nine patients remained in medical treatment, of
which six were able to maintain a stable liver condition
during the 4.9-year follow-up period. However, three
Fig 3. Endovascular management of hepatic vein ou
Angiographic finding of balloon angioplasty from the he
initial procedure to place a transjugular intrahepatic po
Angiography depicts successful stenting procedure over thave shown progressive deterioration of liver condition,documented by the liver biopsy and ultrasound study,
despite adequate medical treatment; all three refused
additional surgical or endovascular treatment. In one of
these three patients, HCC was reported to have devel-
oped soon after the patient stopped the follow-up assess-
ment (4.7 years), and the patient was reported to have
died 1 year after the diagnosis. Therefore, the overall
response to the medical treatment only during the lim-
ited follow-up period was 21.4% (6/28) (Table).
DISCUSSION
Budd-Chiari syndrome is a generic term for various
forms of portal hypertension secondary to obstruction of
hepatic venous outflow, with or without combined IVC
obstruction. Although MOVC 5,7 is known as the most
frequent cause of primary BCS among Africans and Asians,
the hypercoagulable state4,9 remains the most important
cause for Caucasians. Full screening for hypercoagulability,
including collagenous vascular disease, is therefore essential
for the investigation of all the primary BCS. Careful assess-
ment of all other possible causes, such as bacterial infection,
and Behçet’s disease,29,30 also needs to be included to
determine any predisposing factors.
Most of our patients had MOVC-related IVC, he-
patic vein obstruction or stenoses, or both, similar to
other reports from Asia.7,14,17 This unique condition
among our patients supports the congenital/develop-
mental anomaly theory of primary BCS for its etiopatho-
bstruction with angioplasty plus stent procedure. A,
vein outlet to the inferior vena cava (IVC), which is the
stemic shunt (TIPS) to relieve portal hypertension. B,
lloon-dilated and newly established portosystemic shunt.tlet o
patic
rtosygenesis.4,5,7 There have been many reports on the con-
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January 2006106 Lee et alFig 4. Surgical management of inferior vena cava (IVC) occlusion with mesoatrial bypass to relieve portal hyperten-
sion. A, Clinical appearance depicts extensive collateral veins (arrows) to compensate IVC occlusion along the
distended abdominal wall with ascites. B, Operative finding shows extensive collateral veins (arrows) through the
properitoneal layer of abdominal wall. C, End-to-side anastomosis of polytetrafluoroethylene ring graft (arrow) to the
superior mesenteric vein is displayed as a part of mesoatrial bypass surgery to decompress portal hypertension. D,
Mesoatrial bypass graft (arrows) is being led into the mediastinal space anteriorly to the liver for the proximal
anastomosis to the right atrium. E, Duplex ultrasonographic evaluation depicts excellent blood flow through the
superior mesenteric vein after successful decompression of portal hypertension with bypass. F, Excellent antegrade
blood flow through the graft demonstrates well-functioning graft (G) diverting the portal blood flow to the right
atrium. H, Fully restored blood flow within the right hepatic vein displays successful decompression of portal
hypertension by the bypass.
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duplication, abnormal connection and draining, and re-
sidual remnant of embryonal tissue-like webs31-37 Espe-
cially for the pathogenesis of MOVC, this congenital
anomaly theory gains significant support on the basis of
such intriguing embryogenesis of IVC with naturally
increased risk of developmental anomaly.
Angiography has been the mainstay for diagnosis of
BCS, but real-time ultrasonography 21, 22 has shown excel-
lent ability to deliver unique intrahepatic hemodynamic
and pathophysiologic status (Fig 1). We were able to iden-
tify the abnormalities of right, middle, and left hepatic vein
in most patients, in addition to abnormal flow patterns.
Uniphasic flow was the most common abnormality, and
most had an abnormal waveform in one or more hepatic
vein. Intrahepatic collaterals and hepatopetal flow in the
portal vein were common findings.
Direct surgical and endovascular intervention seem to
provide acceptable palliation for most primary BCS lesions
of African/Asian type; this modality of therapy might not
be able to provide same results to Caucasian (Western type)
primary BCS.. Endovascular intervention was accepted as a
safe, less invasive, cost-effective method with less complica-
tion in our institute.
If venous outflow cannot be restored interventionally
or surgically, and liver function continues to deteriorate or
cirrhosis develops, liver transplantation should be consid-
ered.
Our experiences with HCC development in 4 (14.3%)
of 28 patients with primary BCS is compatible with others
reporting a high incidence among African and Asian pa-
tients and shows the striking differences among races.19, 20
In view of distinctive nature of primary BCS as a
precancerous lesion among African/Asian patients with a
high incidence of HCC,18,19 liver transplantation has a
unique role in advanced hepatic failure or a steadily deteri-
Clinical summary of primary Budd-Chiari syndrome manag
1. Medical treatment group (n  9); follow-up, 4.9 years
●n  6: maintained clinically stable condition with comparab
●n  3: deteriorated progressively but refused to receive add
●n  1: reported to have developed liver cancer later.
2. Endovascular treatment group (n  17); follow-up, 4.5 years
A. Balloon angioplasty alone (n  9)
●n  8: excellent to good immediate response and subseque
●n  1: fair response to the first procedure with angioplasty
with subsequent stenting.
●n  2: additional stenting to recurred/progressing lesions w
B. Balloon angioplasty plus stent (n  6)
●n  5: excellent immediate response and subsequent relief o
●n  1: poor response with steady deterioration, and failed s
●n  2: additional stenting to recurred/progressive lesions-
C. Transjugular intrahepatic portosystemic shunt (n  2)
●Excellent response with immediate relief of portal hypertens
3. Surgical treatment (n  2)
●n  1: Mesoatrial bypass; maintains excellent outcome with
●n  1: Liver transplantation; maintains excellent outcome w
years.orating liver condition caused by the primary BCS. Anaggressive approach with liver transplantation may be war-
ranted as a preemptive measure, especially when all the
available methods fail to stop the progression of the disease.
The judgement solely on the basis of clinical response may
be inappropriate, and vigilant surveillance with appropriate
screening of HCC during follow-up using an imaging
modality such as ultrasound is mandated, especially in
African/Asian patients withMOVC as a high-risk group for
HCC development.
CONCLUSIONS
In primary Budd-Chiari syndrome, both endovascular
and surgical interventions provide excellent results and
potentially halt liver parenchymal deterioration caused by
portal hypertension. Both surgical and endovascular proce-
dures may prevent hepatocellular carcinoma as a complica-
tion of primary BCS. However, long-term follow-up stud-
ies are necessary to support this hypothesis.
Liver transplantation would remain ultimate solution
for far advanced liver failure.
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